CUMBERLAND PHARMACEUTICALS INC
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
CPIX$5.37+2.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Equity
| Common stock · Accumulated deficit · Noncontrolling interests · Total equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance, December 31, 2022 | 14,366,616 | $47,474,973 | $(11,208,841) | $(292,126) | $35,974,006 |
| Share-based compensation | 150,260 | 90,156 | — | — | 90,156 |
| Repurchase of common shares | (86,829) | (187,961) | — | — | (187,961) |
| Net income (loss) | — | — | 192,184 | (19,898) | 172,286 |
| Balance, March 31, 2023 | 14,430,047 | $47,377,168 | $(11,016,657) | $(312,024) | $36,048,487 |
| Balance, March 31, 2023 | 14,430,047 | 47,377,168 | (11,016,657) | (312,024) | 36,048,487 | |
|---|---|---|---|---|---|---|
| Share-based compensation | — | 97,877 | — | — | 97,877 | |
| Repurchase of common shares | (99,057) | (171,616) | — | — | (171,616) | |
| Net income (loss) | — | — | 872,200 | (10,046) | 862,154 | |
| Balance, June 30, 2023 | 14,330,990 | 14330990 | $47,303,429 | $(10,144,457) | $(322,070) | $36,836,902 |
| Common stock · Accumulated deficit · Noncontrolling interests · Total equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance, December 31, 2023 | 14,121,833 | $47,091,602 | $(17,488,161) | $(343,572) | $29,259,869 |
| Share-based compensation | 163,991 | 78,754 | — | — | 78,754 |
| Repurchase of common shares | (125,870) | (246,599) | — | — | (246,599) |
| Net income (loss) | — | — | (1,946,263) | 43,791 | (1,902,472) |
| Balance, March 31, 2024 | 14,159,954 | $46,923,757 | $(19,434,424) | $(299,781) | $27,189,552 |
| Balance, March 31, 2024 | 14,159,954 | $46,923,757 | $(19,434,424) | $(299,781) | $27,189,552 |
|---|---|---|---|---|---|
| Share-based compensation | — | 71,958 | — | — | 71,958 |
| Repurchase of common shares | (76,771) | (126,689) | — | — | (126,689) |
| Net loss | — | — | (1,085,612) | (17,025) | (1,102,637) |
| Balance, June 30, 2024 | 14,083,183 | $46,869,026 | $(20,520,036) | $(316,806) | $26,032,184 |
See accompanying Notes to Condensed Consolidated Financial Statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.